Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tinghong Zhang

Showing results (31-40 of 34) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 34 results.
Journal of Nanobiotechnology|January 8, 2021
Development of targeted therapy therapeutics to sensitize triple-negative breast cancer chemosensitivity utilizing bacteriophage phi29 derived packaging RNALong Zhang, Chaofeng Mu, Tinghong Zhang, et al.
ACS Applied Materials & Interfaces|July 3, 2020
Systemic Delivery of Aptamer-Conjugated XBP1 siRNA Nanoparticles for Efficient Suppression of HER2+ Breast CancerLong Zhang, Chaofeng Mu, Tinghong Zhang, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|April 4, 2026
DOT1L Drives Endothelial-to-Mesenchymal Transition and Fibrotic Vascular Remodeling via H3K79 MethylationYaofeng Wang, Xing Peng, Jingjing Chen, et al.
Nature Communications|April 17, 2026
Hijacking innate immunity to enhance mRNA therapeutics by blocking IFN-P-body-XRN1 axis-mediated degradationTinghong Zhang, Xing Peng, Jinling Qin, et al.
Pageof 4

Showing results (31-40 of 34) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 34 results.
Journal of Nanobiotechnology|January 8, 2021
Development of targeted therapy therapeutics to sensitize triple-negative breast cancer chemosensitivity utilizing bacteriophage phi29 derived packaging RNALong Zhang, Chaofeng Mu, Tinghong Zhang, et al.
ACS Applied Materials & Interfaces|July 3, 2020
Systemic Delivery of Aptamer-Conjugated XBP1 siRNA Nanoparticles for Efficient Suppression of HER2+ Breast CancerLong Zhang, Chaofeng Mu, Tinghong Zhang, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|April 4, 2026
DOT1L Drives Endothelial-to-Mesenchymal Transition and Fibrotic Vascular Remodeling via H3K79 MethylationYaofeng Wang, Xing Peng, Jingjing Chen, et al.
Nature Communications|April 17, 2026
Hijacking innate immunity to enhance mRNA therapeutics by blocking IFN-P-body-XRN1 axis-mediated degradationTinghong Zhang, Xing Peng, Jinling Qin, et al.
Pageof 4